Effect of diets containing sucrose vs. D-tagatose in hypercholesterolemic mice

Obesity

Volumn 17, Issue 2, 2009, Pages 269-275

  Police, Sara B ^a   Harris, J Clay ^a   Lodder, Robert A ^a   Cassis, Lisa A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEXOSE; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SUCROSE; TAGATOSE;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; METABOLISM; MOUSE; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; SUGAR INTAKE;

ADIPOSITY; ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; BODY WEIGHT; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; FEMALE; HEXOSES; HYPERCHOLESTEROLEMIA; INSULIN; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, LDL; RISK FACTORS; SUCROSE;

MURINAE; MUS;

EID: 58849155498     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.508     Document Type: Article

References (29)

1. Egger G, Swinburn B. An "ecological" approach to the obesity pandemic. BMJ 1997;315:477-480.
2. Rocchini AP. Obesity hypertension. Am J Hypertens 2002;15(2 Pt 2)S50-S52.
3. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887
4. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-e18.
5. Serdula MK, Mokdad AH, Williamson DF et al. Prevalence of attempting weight loss and strategies for controlling weight. JAMA 1999;282:1353-1358.
6. Lu Y, Levin GV, Donner TW. Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab 2008;10:109-134.
7. Levin GV. Tagatose, the new GRAS sweetener and health product. J Med Food 2002;5:23-36.
8. Rulis AM. Agency response letter GRAS notice nr GRN 000078. US Food and Drug Administration: 〈http://www.cfsan.fda.gov/~rdb/opa-g078.html〉 (2001).
9. Storlien LH, Oakes ND, Pan DA, Kusunoki M, Jenkins AB. Syndromes of insulin resistance in the rat. Inducement by diet and amelioration with benfluorex. Diabetes 1993;42:457-462.
10. Martinez FJ, Rizza RA, Romero JC. High-fructose feeding elicits insulin resistance, hyperinsulinism, and hypertension in normal mongrel dogs. Hypertension 1994;23:456-463.
11. Srinivasan SR, Clevidence BA, Pargaonkar PS, Radhakrishnamurthy B, Berenson GS. Varied effects of dietary sucrose and cholesterol on serum lipids, lipoproteins and apolipoproteins in rhesus monkeys. Atherosclerosis 1979;33:301-314.
12. Swanson JE, Laine DC, Thomas W, Bantle JP. Metabolic effects of dietary fructose in healthy subjects. Am J Clin Nutr 1992;55:851-856.
13. Merkel M, Velez-Carrasco W, Hudgins LC, Breslow JL. Compared with saturated fatty acids, dietary monounsaturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice. Proc Natl Acad Sci USA 2001;98:13294-13299.
14. Gregorevic P, Allen JM, Minami E et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12:787-789.
15. Henriques TA, Huang J, D'Souza SS, Daugherty A, Cassis LA. Orchidectomy, but not ovariectomy, regulates angiotensin II-induced vascular diseases in apolipoprotein E-deficient mice. Endocrinology 2004;145:3866-3872.
16. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004;55:503-517.
17. Buemann B, Toubro S, Raben A, Blundell J, Astrup A. The acute effect of D-tagatose on food intake in human subjects. Br J Nutr 2000;84:227-231.
18. Rada P, Avena NM, Hoebel BG. Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell. Neuroscience 2005;134:737-744.
19. Donner TW, Wilber JF, Ostrowski D. D-tagatose, a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes Obes Metab 1999;1:285-291.
20. Donner TW. The metabolic effects of dietary supplementation with D-tagatose in patients with type 2 diabetes. Diabetes 2006; 55(Suppl 1):A110; 461P.
21. Rognstad R. Gluconeogenesis from D-tagatose by isolated rat and hamster liver cells. FEBS Lett 1975;52:292-294.
22. Seoane J, Gomez-Foix AM, O'Doherty RM et al. Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. J Biol Chem 1996;271:23756-23760.
23. Gergely P, Toth B, Farkas I, Bot G. Effect of fructose 1-phosphate on the activation of liver glycogen synthase. Biochem J 1985;232:133-137.
24. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
25. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007;92:1023-1033.
26. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
27. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-372.
28. Cullen P, Baetta R, Bellosta S et al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol 2003;23:535-542.
29. Saunders JP, Zehner LR, Levin GV. Disposition of D-[U-14C]tagatose in the rat. Regul Toxicol Pharmacol 1999;29(2 Pt 2):S46-S56.